Table 1.
Clinicopathologic characteristics of all patients in this study
| Characteristics | Cohort 1 (n = 61) | Cohort 2 (n = 49) | Cohort 3 (n = 3) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 57 (93.4) | 42 (85.7) | 3 (100.0) |
| Female | 4 (6.6) | 7 (14.3) | 0 |
| Age (years) | |||
| Mean ± SD | 59.5 ± 8.8 | 59.4 ± 8.3 | 62.7 ± 3.5 |
| Median (min, max) | 61.0 (43.0, 74.0) | 59.0 (34.0, 72.0) | 63.0 (59.0, 66.0) |
| > 60, n (%) | 32 (52.5) | 21 (42.9) | 2 (66.7) |
| ≤ 60, n (%) | 29 (47.5) | 28 (57.1) | 1 (33.3) |
| Smoking status, n (%) | |||
| Current smoker/quitted | 55 (90.2) | 38 (77.6) | 3 (100.0) |
| Non-smoker | 6 (9.8) | 11 (22.4) | 0 |
| Staging, n (%) | |||
| Stage IIIB | 8 (13.1) | 3 (6.1) | 1 (33.3) |
| Stage IIIC | 1 (1.6) | 2 (4.1) | 0 |
| Stage IV A | 29 (47.5) | 27 (55.1) | 1 (33.3) |
| Stage IVB | 23 (37.7) | 17 (34.7) | 1 (33.3) |
| Best of response to PD-1 mAb | |||
| CR | 1 (1.6) | NA | 0 |
| PR | 13 (21.3) | NA | 2 (66.7) |
| StD | 30 (49.2) | NA | 1 (33.3) |
| PD | 15 (24.6) | NA | 0 |
| NE | 2 (3.3) | NA | 0 |
SD standard deviation, PD-1 programmed cell death protein 1, mAb monoclonal antibody, CR complete response, PR partial response, StD stable disease, PD progressive disease, NE not evaluable according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria, NA not available